search
Back to results

Using Nasal High Flow From Birth in Premature Infants - a Pilot Study

Primary Purpose

Premature Birth

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Vapotherm Precision Flow
Sponsored by
Ashford and St. Peter's Hospitals NHS Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional supportive care trial for Premature Birth focused on measuring nasal High Flow, premature baby, CPAP (Continuous positive airways pressure)

Eligibility Criteria

24 Weeks - 30 Weeks (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Parental consent
  • 24+0 to 30+0 weeks(agreed dates) gestation born alive
  • Breathing spontaneously at birth or soon after with minimal resuscitation
  • Oxygen saturations >90% by 5 minutes

Exclusion Criteria:

  • No parental consent
  • Born in poor condition and unlikely to survive
  • Needing resuscitation including intubation and/or chest compressions
  • Not breathing and thus needing intubation
  • Oxygen saturations <90% by 5 minutes
  • <24 weeks gestation
  • >30 weeks gestation

Sites / Locations

  • Neonatal ICU, St Peter's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

nasal High Flow applied

Arm Description

Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device

Outcomes

Primary Outcome Measures

Need for endotracheal intubation prior to admission to Neonatal Unit
Babies who are clinically stable will not require intubation prior to admission to the neonatal unit.

Secondary Outcome Measures

Development of pneumothorax within 24 hours of birth
Pneumothorax is a rare but important outcome measure.
Requirement for endotracheal intubation and surfactant administration after admission to neonatal unit within 24 hours of birth
Intubation and surfactant administration after admission within the first 24 hours indicates severe respiratory distress syndrome requiring treatment according to agreed local protocols
Development of bronchopulmonary dysplasia defined as oxygen requirement at 36 weeks corrected age
Bronchopulmonary dyplasia is an important outcome of the respiratory management of premature babies. We use the standard definition of an ongoing oxygen requirement at 36 weeks corrected age with compatible X-ray changes.

Full Information

First Posted
November 11, 2013
Last Updated
August 11, 2016
Sponsor
Ashford and St. Peter's Hospitals NHS Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT01991886
Brief Title
Using Nasal High Flow From Birth in Premature Infants - a Pilot Study
Official Title
A Pilot Study to Determine the Feasibility of the Use of Nasal High Flow From Birth in Premature Infants Born at Less Than or Equal to 30 Week Gestational Age.
Study Type
Interventional

2. Study Status

Record Verification Date
August 2016
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
January 2015 (Actual)
Study Completion Date
March 2015 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ashford and St. Peter's Hospitals NHS Trust

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Recent large studies have shown that not all premature babies need to be intubated (have a breathing tube inserted) and ventilated, nor do they all need to be given lung surfactant routinely. Those studies showed that even very small babies can be safely supported using nasal Continuous Positive Airway Pressure (nCPAP) which is applied tightly to the nose using nasal prongs. This is a type of noninvasive ventilation (NIV) so that the babies continue to breath, albeit with additional support to reduce their work of breathing. However nCPAP has some drawbacks, including that it can cause skin damage to the nose, and that the heating and humidification of the gas is not always sufficient. We have been using, for over 5 years, a different system to support babies after routine intubation. This is another type of noninvasive ventilation called nasal High Flow (nHF) for which we use a Vapotherm Precision Flow device. Published trials show that it is at least as effective as nCPAP to provide NIV and to prevent the subsequent need for intubation and/or surfactant. However nHF is superior to nCPAP in respect it does not cause nose damage and its heating and humidification is excellent. This pilot study aims to describe and evaluate the use of nHF, using a standard commercially available system (Precision Flow, Vapotherm Inc.), from birth, in babies born less than 30 completed weeks gestation, with a view to avoiding intubation and ventilation. This study is important to establish the feasibility of using nHF immediately after birth.
Detailed Description
We propose to pilot the use of this mobile nHF unit, using the Vapotherm Precision Flow device, in the premature population of babies who would normally be either intubated and given surfactant routinely, or be maintained on nCPAP until arrival on the Neonatal Intensive Care Unit (NICU) then transferred onto nHF. Parents will be informed about the pilot and their permission will be sought. We aim to recruit 40 babies less than 30 weeks gestation. The reason for undertaking a pilot study of this nature is to establish feasibility and proof of concept. It is not designed to be compared to using nCPAP to stabilise babies immediately after birth (although that will be the next and logical progression if this proves to be a feasible technique). The hypothesis is that using nHF to stabilise babies immediately after birth will confer the same advantages as using nCPAP to stabilise babies in this way, which has been demonstrated in the worldwide literature. For units such as ours who use nHF in preference to nCPAP, this will be an important step in further defining the management of these babies after birth. There is evidence that nHF is at least as good as nCPAP in preventing intubation and reducing lung disease, and it may also offer additional advantages from humidification and reduction in nasal trauma. The major challenge for this pilot project will be to identify eligible deliveries in a timely manner to ensure that a suitable member of staff is available to speak to parents and gain consent. Once a delivery has been identified and the parents have agreed to take part, then the following process will take place to manage the newborn baby. Check the mobile nHF unit The mobile nHF unit should be kept plugged in so that the uninterruptable power supply (UPS) is fully charged To use it, unplug it to check that the UPS is functioning (green lights indicate full charge), set up a Vapotherm circuit(as per normal routine) and start the machine running on UPS power supply. Gas supply should be from the cylinders to check that the pressures are 50bar in both air and oxygen cylinders Set the temperature to 37 degrees Celsius Once running, turn the unit off if not immediately needed or plug into the mains power and gas(es) where available to conserve gas. The unit can be run on a flow of 1 litre/minute whilst "ticking over" to conserve cylinder gas if needed. The prongs should be attached to the circuit. Once the baby is born Place the baby in a polythene bag (as per normal practice) Ensure the baby is breathing. If not, or the baby is bradycardic, then normal resuscitation measures should be applied. It will only be appropriate to apply the mobile nHF if the baby is breathing and is clinically stable. Once the baby is born, increase the flow to 6 litres/min If the baby is breathing then apply the nHF prongs and observe carefully Suction should only be applied gently, if needed to remove excessive secretions in the mouth and throat. Babies on high flow will often "blow bubbles" and there may be lung fluid in the throat, but suction should not be vigorous Apply a saturation monitor (as per normal practice) to check Heart Rate (HR) and Oxygen Saturation (SaO2). Dry the baby's face sufficiently to be able to apply duoderm dressing to stick down the prongs to the cheeks. Observe the baby carefully, ensure attention to thermal care and inform the parents about progress. As soon as the baby appears stable, move to NICU as per normal practice Transfer to NICU Two people are needed to effect the transfer from labour ward/theatre to NICU, one to move the mobile nHF and one to move the resuscitaire. On arrival in NICU, plug the mobile nHF into gas and power supplies (switch the manifold over) Ensure that there is a second, cotside Vapotherm (empty) unit Leave the baby in the resuscitaire and check the admission temperature. Stop the mobile nHF, remove the cartridge and place it into the cotside Vapotherm unit. Start it running, it should run straight away. Ensure that the correct temperature, flow and Fraction Of Inspired Oxygen (FiO2) are set This process takes less than 20 seconds and as the baby is breathing will not be detrimental Transfer the baby into the incubator and commence normal admission practices Document the resuscitation clearly in the baby's notes Cleaning and charging the mobile nHF o Remove the mobile nHF, clean the Vapotherm Precision flow nHF unit. Ensure the cylinders are switched off and plug into the wall to recharge the UPS.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Premature Birth
Keywords
nasal High Flow, premature baby, CPAP (Continuous positive airways pressure)

7. Study Design

Primary Purpose
Supportive Care
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
28 (Actual)

8. Arms, Groups, and Interventions

Arm Title
nasal High Flow applied
Arm Type
Experimental
Arm Description
Application of nasal High Flow 6-7l/min via nasal prongs after birth using a mobile Vapotherm Precision Flow device
Intervention Type
Device
Intervention Name(s)
Vapotherm Precision Flow
Other Intervention Name(s)
nasal High Flow device, nasal heated humidified high flow cannula
Intervention Description
Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
Primary Outcome Measure Information:
Title
Need for endotracheal intubation prior to admission to Neonatal Unit
Description
Babies who are clinically stable will not require intubation prior to admission to the neonatal unit.
Time Frame
From birth
Secondary Outcome Measure Information:
Title
Development of pneumothorax within 24 hours of birth
Description
Pneumothorax is a rare but important outcome measure.
Time Frame
First 24 hours after birth
Title
Requirement for endotracheal intubation and surfactant administration after admission to neonatal unit within 24 hours of birth
Description
Intubation and surfactant administration after admission within the first 24 hours indicates severe respiratory distress syndrome requiring treatment according to agreed local protocols
Time Frame
First 24 hours after admission to neonatal unit
Title
Development of bronchopulmonary dysplasia defined as oxygen requirement at 36 weeks corrected age
Description
Bronchopulmonary dyplasia is an important outcome of the respiratory management of premature babies. We use the standard definition of an ongoing oxygen requirement at 36 weeks corrected age with compatible X-ray changes.
Time Frame
Defined at 36 weeks corrected age

10. Eligibility

Sex
All
Minimum Age & Unit of Time
24 Weeks
Maximum Age & Unit of Time
30 Weeks
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Parental consent 24+0 to 30+0 weeks(agreed dates) gestation born alive Breathing spontaneously at birth or soon after with minimal resuscitation Oxygen saturations >90% by 5 minutes Exclusion Criteria: No parental consent Born in poor condition and unlikely to survive Needing resuscitation including intubation and/or chest compressions Not breathing and thus needing intubation Oxygen saturations <90% by 5 minutes <24 weeks gestation >30 weeks gestation
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Peter Dr Reynolds, PhD
Organizational Affiliation
Ashford and St. Peter's Hospitals NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Neonatal ICU, St Peter's Hospital
City
Chertsey
State/Province
Surrey
ZIP/Postal Code
KT16 0PZ
Country
United Kingdom

12. IPD Sharing Statement

Plan to Share IPD
Undecided
Citations:
PubMed Identifier
26733541
Citation
Reynolds P, Leontiadi S, Lawson T, Otunla T, Ejiwumi O, Holland N. Stabilisation of premature infants in the delivery room with nasal high flow. Arch Dis Child Fetal Neonatal Ed. 2016 Jul;101(4):F284-7. doi: 10.1136/archdischild-2015-309442. Epub 2016 Jan 5.
Results Reference
derived

Learn more about this trial

Using Nasal High Flow From Birth in Premature Infants - a Pilot Study

We'll reach out to this number within 24 hrs